Sacubitril/Valsartan Affects Pulmonary Arterial Pressure in Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension

Abstract

Sacubitril/valsartan significantly reduced mPAP in patients with HFpEF-PH, independent of loop diuretic management, together with improvement in functional capacity, lung congestion, and QoL. Sacubitril/valsartan may be a therapeutic alternative in HFpEF-PH.